CELLECTAR BIOSCIENCES INC (CLRB) Stock News
NASDAQ:CLRB - Nasdaq - US15117F8077 - Common Stock - Currency: USD
CLRB Latest News, Press Relases and Analysis
Top movers in Wednesday's after hours session
The regular session of the US market on Wednesday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.
The trading volume of these stocks is deviating from the norm in today's session.
These stocks have an unusual volume in today's session
Cellectar Biosciences Announces One-for-Thirty Reverse Stock Split
Cellectar Biosciences Announces One-for-Thirty Reverse Stock Split
FLORHAM PARK, N.J., June 18, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB), a late-stage clinical biopharmaceutical company focused...
Cellectar Biosciences Provides Update on CLOVER-2 Phase 1 Clinical Trial of Iopofosine I 131 in Pediatric Patients with Relapsed/Refractory High-Grade Glioma
In Patients Receiving a Minimum of 55 mCi an Average 5.4 Months of PFS was Observed: Twice the Reported 2.25 Median
Cellectar Biosciences Provides Update on CLOVER-2 Phase 1 Clinical Trial of Iopofosine I 131 in Pediatric Patients with Relapsed/Refractory High-Grade Glioma
In Patients Receiving a Minimum of 55 mCi an Average 5.4 Months of PFS was Observed: Twice the Reported 2.25 Median...
Which stocks are gapping on Thursday?
The market is filled with gapping stocks in Thursday's session. Let's discover which stocks are showing gap-ups and gap-downs.
Are Medical Stocks Lagging Anixa Biosciences (ANIX) This Year?
Here is how ANIXA BIOSCIENCES INC (ANIX) and Cellectar Biosciences, Inc. (CLRB) have performed compared to their sector so far this year.
Mentions: ANIX
Cellectar Biosciences Enters into Common Stock Agreements to Raise $2.5 Million Priced at Market Under Nasdaq Rules
Cellectar Biosciences Enters into Common Stock Agreements to Raise $2.5 Million Priced at Market Under Nasdaq Rules
FLORHAM PARK, N.J., June 05, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused...
Stay updated with the stocks that are on the move in today's after-hours session.
Discover the top movers in Wednesday's after-hours session and stay informed about the post-market dynamics.
What's going on in today's session
Keep an eye on the top gainers and losers in Wednesday's session, as they reflect the most notable price movements.
Curious about the most active stocks on Wednesday?
Let's dive into the action on the US markets on Wednesday. Here are the most active stocks that are driving the market today.
Which stocks are experiencing notable movement on Wednesday?
Let's have a look at what is happening on the US markets in the middle of the day on Wednesday. Below you can find the top gainers and losers in today's session.
Wednesday's session: gap up and gap down stocks
Let's delve into the US markets on Wednesday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.
Cellectar Granted U.S. FDA Breakthrough Therapy Designation for Iopofosine I 131 in Waldenstrom Macroglobulinemia (WM)
Cellectar Granted U.S. FDA Breakthrough Therapy Designation for Iopofosine I 131 in Waldenstrom Macroglobulinemia (WM)
Designation Supported by CLOVER WaM Phase 2 Study DataWhich Reported an 83.6% Overall Response Rate (ORR) Seeking Guidance from EMA to Determine if CLOVER...
Zacks Industry Outlook Highlights Insulet, MacroGenics, Cellectar Biosciences and Allurion Technologies
Insulet, MacroGenics, Cellectar Biosciences and Allurion Technologies are part of the Zacks Industry Outlook article.
Tariff Uncertainty Fuels Copper Price Volatility
Copper prices are experiencing volatility due to shifts in trade policies, tariff deals, and concerns over global economic growth.
4 Medical Product Stocks to Watch From a Challenging Industry
The U.S. government's tariff imposition, especially on China, is likely to keep supply chains under pressure for the Zacks Medical Products industry. PODD, MGNX, CLRB and ALUR reflect the favorable fundamentals.
Cellectar Biosciences Reports First Quarter 2025 Financial Results and Provides a Corporate Update
Cellectar Biosciences Reports First Quarter 2025 Financial Results and Provides a Corporate Update
Company Seeking Conditional Approval from European Medicines Agency (EMA) for Iopofosine I 131 in Waldenstrom Macroglobulinemia based upon CLOVER WaM Phase...
Cellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Tuesday, May 13, 2025
Cellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Tuesday, May 13, 2025
FLORHAM PARK, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused...
Cellectar Announces Plan to Explore Strategic Alternatives
Cellectar Announces Plan to Explore Strategic Alternatives
FLORHAM PARK, N.J., April 30, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company...
4 Medical Product Stocks to Buy From a Challenging Industry
The U.S. government's tariff imposition, especially on China, is likely to keep supply chains under pressure for the Zacks Medical Products industry. PODD, MGNX, CLRB and ALUR are likely to gain from the favorable factors.
Cellectar Biosciences Reports Financial Results for Year Ended 2024 and Provides a Corporate Update
Cellectar Biosciences Reports Financial Results for Year Ended 2024 and Provides a Corporate Update
Achieves alignment with U.S. Food and Drug Administration (FDA) on regulatory path for potential accelerated approval of iopofosine I 131 as a treatment...